Round 2 for IPO players

OK, this has very little to do with SRX, other than the dudes behind it.

However as Starfish was quoted in one of my posts a couple of weeks back I thought some SRXers may find this of some interest. Apologies to anyone who considers this a cross promotion.

Maybe one to watch. As always with companies at this stage there is very high risk of zero return, but I tend to back the people with early stage.

Would be really interested in any of the medical or other qualified posters views. Maybe on the IPOs thread.

http://www.theaustralian.com.au/bus...-for-ipo-players/story-fnjw8txa-1227600861382

Some of the key players behind Sirtex Medical’s initial public offering have teamed up for another biotechnology float.
Armaron Bio, which is developing treatments for cardiac recovery, will kick off an investor roadshow this week ahead of an IPO that would value the company at about $100 million.
KTM Capital, which floated Sirtex in 2000, is advising on the deal. The other Sirtex link is Armaron director Michael Panaccio, who is a principal of the company’s major shareholder, Starfish Ventures.

Mr Panaccio was previously an investment manager at Nomura’s venture capital arm JAFCO, where he looked after the firm’s investment in Sirtex and served as a director of the medical device company after the float.
Sirtex listed in 2000 at $1 and closed at $38.30 on Friday.
Other major Armaron shareholders include MedImmune Ventures, the venture capital arm of global pharmaceuticals giant AstraZeneca Group, and the University of Melbourne.
The Melbourne-based Armaron will enter a proof of concept phase 2 trial in heart failure this quarter.
--------------------------------